ストックスクリーナーアプリを入手
3.01
1.35%
0.04
アフターアワーズ：
3.01
iBio Inc (IBIO) 最新ニュース
iBio Inc. stock rises Friday, outperforms market - MarketWatch
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch
iBio Inc. stock falls Monday, still outperforms market - MarketWatch
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
I: Weekly TechBio News - substack.com
iBio Announces Successful Closing of Private Placement OfferingOn January 10, 2025, iBio, Inc. (NYSE American: IBIO) announced the completion of a private placement offering, marking an important development for the company. The securities purchase a - Defense World
iBio director William Clark purchases $4,999 in common stock - Investing.com India
iBio director Parada acquires $499,998 in common stock By Investing.com - Investing.com Australia
iBio director William Clark purchases $4,999 in common stock By Investing.com - Investing.com Australia
Felipe Duran Increases Stake in iBio Inc with Recent Share Purch - GuruFocus.com
Director David Arkowitz Acquires 18,382 Shares of iBio Inc (IBIO) - GuruFocus.com
Insider Buying: Gary Sender Acquires 9,191 Shares of iBio Inc (I - GuruFocus.com
Ibio's chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Australia
iBio director Gary Sender purchases $24,999 in common stock By Investing.com - Investing.com Australia
Ibio CEO Brenner Martin acquires $24,999 in stock By Investing.com - Investing.com Australia
Ibio's CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Australia
iBio director Arkowitz purchases $49,999 in common stock By Investing.com - Investing.com Australia
Ibio’s CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Nigeria
Ibio’s chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Nigeria
iBio director Arkowitz purchases $49,999 in common stock - Investing.com India
iBio Inc. stock falls Monday, underperforms market - MarketWatch
Ibio's CFO Duran Felipe buys $24,999 in common stock - Investing.com
Ibio's chief legal officer Marc Banjak buys $24,999 in stock - Investing.com
iBio Announces New Investments from Board Members and Officers - The Manila Times
iBio Board Backs AI-Driven Obesity Drug Platform with $650K Strategic Investment - StockTitan
** - Defense World
iBio Advances Antibody Development for Obesity Treatment - TipRanks
Ibio licenses long-acting anti-myostatin antibody from Astralbio - BioWorld Online
iBio develops antibody for cardiometabolic disorders and obesity - Investing.com
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio - The Manila Times
iBio and AstralBio Breakthrough: Novel Antibody Targets Obesity and Diabetes Through Activin E Inhibition - StockTitan
iBio Inc. stock rises Monday, still underperforms market - MarketWatch
iBio Enters Exclusive License Agreement with AstralBio for Development of Anti-Myostatin Antibody - Defense World
SABBY MANAGEMENT, LLC Acquires 19,250 Shares of iBio Inc - GuruFocus.com
iBio Inc. stock rises Friday, still underperforms market - MarketWatch
iBio Expands Pipeline with New Antibody Agreement - Yahoo Finance
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform - AOL
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio - The Manila Times
iBio expands cardiometabolic and obesity program (NYSE:IBIO) - Seeking Alpha
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):